Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First People's Hospital of Foshan, Foshan, Guangdong, China
Contact: Study coordinator (Wei Wang, Ph.D) · 8618666392971
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Yanhong Deng, Ph.D) · dengyanh@mail.sysu.edu.cn · 8613925106525
Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
Contact: Study coordinator (Wen-Ling Wang, Ph.D) · 8613885077539

Study leads

Yanhong Deng, Ph.D
Principal Investigator
Sixth Affiliated Hospital, Sun Yat-sen University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

BRAF V600E · Colorectal Cancer · Sintilimab

Abroad (travel likely)RecruitingPHASE2

Beijing, China · Wuhan, China

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Cerritos, United States · Los Angeles, United States

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States